Search results for: Androstane-3a, 17b-diol 5a Antibody
#34514104 2021/06/04 To Up
promotes gastric cancer progression by upregulating semaphorin 5A expression via ERK/MMP9 signaling.() infection is the strongest risk factor for the occurrence and development of gastric carcinoma. However, the molecular mechanism underlying induced pathogenesis has not yet been fully characterized. Here, we explored whether upregulates semaphorin 5A to promote gastric cancer progression via the extracellular regulated protein kinases/matrix metalloproteinase (ERK/MMP9) signaling pathway. In this study, upregulated semaphorin 5A expression and . Using the human gastric carcinoma cell lines SGC7901, SGC7901-siScrambled, and SGC7901-siSema 5A, our studies showed that increased the proliferation, growth, migration, and invasiveness of gastric cancer cells via its effects on semaphorin 5A and that increased the expression of MMP9 in gastric cancer cells via the semaphorin 5A-mediated ERK signaling pathway. Further analysis revealed that the ERK inhibitor PD98059 and MMP9 antibody (Ab) attenuated induced gastric cancer cell invasion and metastasis through a semaphorin 5A-dependent mechanism. In conclusion, could promote gastric cancer progression in a semaphorin 5A-dependent manner via the ERK/MMP9 signaling pathway. Semaphorin 5A and its related signaling molecules potentially represent latent targets for related gastric cancer therapy.
Guoqing Pan, Xianwen Wang, Yingxia Wang, Rui Li, Geng Li, Ying He, Shiyue Liu, Yonghui Luo, Liqiong Wang, Zi Lei
1905 related Products with: promotes gastric cancer progression by upregulating semaphorin 5A expression via ERK/MMP9 signaling.
#34473462 // To Up
Antineutrophil cytoplasmic antibody (ANCA) vasculitis: pathophysiology, diagnosis, and the evolving treatment landscape.The antineutrophil cytoplasmic antibody (ANCA) vasculitides include several closely related, often severe, multisystem autoimmune diseases characterized by antibodies against serine proteinase 3 (PR3) or myeloperoxidase. Loss of tolerance to these antigens triggers a cascade of events, beginning with the priming of neutrophils by proinflammatory cytokines and complement activation, translocation of ANCA-specific antigens to the plasma membrane, neutrophil hyperactivation, and further activation of the alternative complement pathway, leading to tissue damage and the clinical manifestations of ANCA vasculitis. Due to the heterogeneity in presentation of these diseases, diagnosis is often substantially delayed, leading to poor outcomes. The current treatment pathway for most patients involves induction with cyclophosphamide or rituximab in combination with glucocorticoids, followed by a maintenance phase with rituximab, azathioprine, or methotrexate, during which time glucocorticoids are tapered. Current therapies are often effective in inducing and maintaining remission but are associated with a range of toxicities. Several new therapies are in development for ANCA vasculitis. Avacopan, an orally administered inhibitor of the complement fragment 5a (C5a) receptor, has been assessed in a phase 3 clinical trial and may play a role in reducing the cumulative glucocorticoid dose. Preliminary data suggest that cluster of differentiation (CD) 80 and CD86 blockade with abatacept may also have a role in the management of ANCA vasculitis. There is an unmet need for additional therapeutic options for patients with these diseases.
Curry L Koening, Irene von Hennigs
1703 related Products with: Antineutrophil cytoplasmic antibody (ANCA) vasculitis: pathophysiology, diagnosis, and the evolving treatment landscape.100ul100μg50 ug 100ug100ug100μg1000 tests100μg 100ul100ul
#34367648 2021/07/26 To Up
Expanding the Deceased Donor Pool in Manitoba Using Hepatitis C-Viremic Donors: Program Report.The ongoing shortage of organs for transplant combined with Manitoba having the highest prevalence of end-stage renal disease (ESRD) in Canada has resulted in long wait times on the deceased donor waitlist. Therefore, the Transplant Manitoba Adult Kidney Program has ongoing quality improvement initiatives to expand the deceased donor pool. This clinical transplant protocol describes the use of prophylactic pan-genotypic direct-acting anti-viral agents (DAA) for transplanting hepatitis C (HCV)-viremic kidneys (HCV antibody positive/nucleic acid [nucleic acid amplification testing, NAT] positive) to HCV-naÃ¯ve recipients as routine standard of care. We will evaluate the provincial implementation of this protocol as a prospective observational cohort study.
Susan Cuvelier, Paul Van Caeseele, Matthew Kadatz, Kathryn Peterson, Siyao Sun, Nancy Dodd, Kim Werestiuk, Joshua Koulack, Peter Nickerson, Julie Ho
2617 related Products with: Expanding the Deceased Donor Pool in Manitoba Using Hepatitis C-Viremic Donors: Program Report.1 Product tipe: Instrumen1
#34268527 2021/07/07 To Up
Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19.Interim immunogenicity and efficacy data for the Ad26.COV2.S vaccine for COVID-19 have recently been reported . We describe here the 8-month durability of humoral and cellular immune responses in 20 individuals who received one or two doses of 5Ã-10 vp or 10 vp Ad26.COV2.S and in 5 participants who received placebo . We evaluated antibody and T cell responses on day 239, which was 8 months after the single-shot vaccine regimen (N=10) or 6 months after the two-shot vaccine regimen (N=10), although the present study was not powered to compare these regimens . We also report neutralizing antibody responses against the parental SARS-CoV-2 WA1/2020 strain as well as against the SARS-CoV-2 variants D614G, B.1.1.7 (alpha), B.1.617.1 (kappa), B.1.617.2 (delta), P.1 (gamma), B.1.429 (epsilon), and B.1.351 (beta).
Dan H Barouch, Kathryn E Stephenson, Jerald Sadoff, Jingyou Yu, Aiquan Chang, Makda Gebre, Katherine McMahan, Jinyan Liu, Abishek Chandrashekar, Shivani Patel, Mathieu Le Gars, Anne Marit de Groot, Dirk Heerwegh, Frank Struyf, Macaya Douoguih, Johan van Hoof, Hanneke Schuitemaker
1691 related Products with: Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19.1000 ml 100ug100 ml3x 500 ml0.25 mg100ug50 mL1 ml 125 ml
Error loading info... Pleas try again later.
#33895070 2021/04/08 To Up
Autoimmune pancytopenia after liver transplantation: A case report.Autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), and autoimmune neutropenia (AIN) are reported in the literature after liver, intestinal, heart, pancreas, and kidney transplants. We report a case of autoimmune pancytopenia (AIHA, AIN and ITP) 9 years after liver transplantation with confirmed erythrocyte and neutrophil auto-antibodies.
Melca Maria Oliveira Barros, Fauze Lutfe Ayoub, Giovanna Lemos, Kelly Cristina Brasileiro, Priscilla Brito da Silva Icibaci, Elyse Moritz, Juliana Oliveira Martins, Carolina Bonet Bub, Akemi Kuroda Chiba, Jose Orlando Bordin
#33884465 2021/04/21 To Up
[Avacopan in ANCA-associated vasculitis: the ADVOCATE trial].
Frank Moosig, Julia Holle11 Set1 mg
No related Items
Error loading info... Pleas try again later.
#33709164 2021/03/11 To Up
[Cortisone-free rheumatology-Vasculitides].Glucocorticoids (GC) still represent an essential pillar of treatment in the phase of remission induction of vasculitides, which are often organ or life-threatening; however, they entail aÂ significant potential for side effects. In the phase of remission maintenance prednisolone should be reduced to 7.5â¯mg/day or less. Whether a discontinuation can alway be achieved for any form of vasculitis without increasing relapse rates, is unclear. By the use of biologics, e.g. tocilizumab in giant cell arteritis (GCA), aÂ fast tapering and discontinuation of GC seems to be more easily achievable compared to using aÂ GC monotherapy regimen. Avacopan could in the future be an efficient agent to spare GC in the phase of remission induction in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), e.g. granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Mepolizumab is aÂ promising option to reduce the use of GC in eosinophilic granulomatosis with polyangiitis (EGPA).
Julia U Holle, Frank Moosig0.25 mg5 g 5 G1 mg50 mg100 1KG1 Bottle/Unit24 reactions 1 ml1 mg
#33677084 2021/03/04 To Up
A simple method to purify recombinant HCV core protein expressed in Pichia pastoris for obtaining virus-like particles and producing monoclonal antibodies.In this study, we describe an optimized method of obtaining virus-like particles (VLPs) of the recombinant hepatitis C virus (HCV) core protein (HCcAg) expressed in yeast cells (Pichia pastoris), which can be used for the construction of diagnostic test systems and vaccine engineering. The described simplified procedure was developed to enable in vitro self-assembly of HCcAg molecules into VLPs during protein purification. In brief, the HCcAg protein was precipitated from yeast cell lysates with ammonium sulfate and renatured by gel filtration on Sephadex G-25 under reducing conditions. VLPs were self-assembled after the removal of the reducing agent by gel filtration on Sephadex G-25. Protein purity and specificity were evaluated by SDS-PAGE and immunoblotting analysis. The molecular mass of VLPs and their relative quantity were measured by HPLC, followed by confirmation of VLPs production and estimation of their shape and size by transmission electron microscopy. As a result, we obtained recombinant HCcAg preparation (with ~90% purity) in the form of VLPs and monomers, which has been used to produce hybridomas secreting monoclonal antibodies (mAbs) against HCcAg.
Anastasia Pechelyulko, Zhanna Andreeva-Kovalevskaya, Dmitriy Dmitriev, Viacheslav Lavrov, Yulia Massino, Alexey Nagel, Olga Segal, Olga S Sokolova, Alexander Solonin, Yulia Tarakanova, Alexander Dmitriev
2793 related Products with: A simple method to purify recombinant HCV core protein expressed in Pichia pastoris for obtaining virus-like particles and producing monoclonal antibodies.100 100.00 ug1 mg50010ìg100.00 ug100 1001mg100.00 ug500 ug100
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia